The Perseus PCI Vaccine

Oncologist Information Guide

Clinical research studies over the last several decades have clearly demonstrated the e cacy of immunotherapy as a treatment modality for cancer.
Because the most e ective tumor immunotherapeutic strategies require the use of patient-specic tumor tissue and the patients own immune cells, this new approach to treatment is a highly personalized individual therapy. Patient-specic personalized therapies, while highly e ective in many cases, are not compatible with the business model of the existing pharmaceutical industry. As a result of this incompatibility between newly emerging personalized therapies and traditional pharmaceutical companies, a new wave of smaller companies o ering these new therapies has emerged. Perseus, Inc. o ers personalized immunotherapy for patients with solid tumors. The therapy o ered by Perseus is an extension of twelve years of clinical trials performed in the U.S. under FDA guidance and approval, and Perseus continues to

carry out clinical research and trials in the U.S. toward nal FDA approval. In order to provide this exciting new therapy to more patients today, Perseus has applied for and received permission from the Health Practice Commission of the Cayman Islands, a British Overseas Territory with an exemplary British-based medical system, to treat patients with solid tumors utilizing their patented immunotherapy. The Personalized Cancer Immunotherapeutics (PCI) Vaccine therapy o ered by Perseus involves the introduction of the entire contents of the patients tumor cells into the

cytoplasm of the patients own dendritic cells in order to e ectively present any and all patient-specic tumor antigens via the dendritic cells MHC Class I molecules to elicit a strong CD8 CTL response against the patients tumor. While the Phase I and II clinical trials that Perseus performed showed signicant e cacy in retarding or eliminating tumors in Stage IV patients with several solid tumors, no signicant adverse e ects were observed, and the quality of life of patients was maintained or improved. In order to prepare multiple doses of this therapeutic tumor vaccine,

Renowned cancer researcher Dr. Thomas Wagner, creator of the Perseus PCI Vaccine

The Perseus Medical T eam

Dr. Sook Yin, our highly a cclaimed treating p hysician based in the Cayman Islands, will coordinate your treatment protocol once you arrive on Grand Cayman. Dr. Yin, who has practiced medicine in the Cayman Islands for 25 years, is a member of both the British Medical Association and The American Academy of Family Physicians. She is the Founder and Medical Director of Seven Mile Medical Clinic in the Cayman Islands. She has been the Medical Director of Cayman Islands Cancer Society since April 2001. Dr. Yin is driven by a passion to reduce the inciden ce of cancer in the Cayman Islands and the world at large. She works with research groups in the United States to deliver cancer treatments to patients in the Cayman Islands. The Perseus medical team in the United States includes: Marcus Blackstone, M.D. Pauline Nichol, PA-C

Perseus requires that the patients surgeon provide two small (approximately 1 mg each) samples of the patients tumor tissue devoid of any non-tumor tissue, to be frozen at 20 C (-4 F) and taken by the patient to the Perseus health-care facility in the Cayman Islands. One sample will be used for making the series of four vaccines, and the other will be kept frozen as a backup specimen. Once a patients tumor sample is harvested, the patient will t ravel to Grand Cayman, where he or she will have 100 mls of blood drawn and the personalized PCI Vaccine will be prepared. The patient will receive

the rst PCI Vaccine during the initial trip, and then return once every month for three months for subsequent vaccines. Each vaccination consists of a single intradermal injection of one million patient tumor ti ssue-activated dendritic cells. If you would like more information on how to include the PCI Vaccine in your patients treatment protocol, contact our Director of Clinical Operations for more information. Pauline Nichol, PA-C, Director of Clinical Operations Pauline.nichol@perseuspci.com (866) 830-9320

TM

Personalized Cancer Immunotherapeutics